Perrigo Plays To OTC Strength With GoodSense Firm Acquisition
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Geiss, Destin & Dunn's GoodSense brand includes more than 1,500 OTC drugs and nutritional products. The deal could help diminish the impact of earnings headwinds on Perrigo's branded consumer health and Rx generic topicals businesses.
You may also be interested in...
Perrigo Hopes Esomeprazole Helps Make Private Label OTCs A Bright Spot
The firm lowers its 2016 guidance as its European branded OTC drug and nutritional product business and its Rx topicals business appear to be major obstacles to escaping its earnings slump.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.